Piper Sandler Cuts Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target to $20.00

Amphastar Pharmaceuticals (NASDAQ:AMPH) had its price objective cut by equities researchers at Piper Sandler from $21.00 to $20.00 in a research note issued on Friday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Piper Sandler’s price objective points to a potential downside of 6.06% from the stock’s previous close.

Other equities analysts also recently issued reports about the company. Weiss Ratings reiterated a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, July 8th. Barclays reduced their price target on Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating for the company in a research report on Wednesday, June 3rd. Jefferies Financial Group reaffirmed a “hold” rating and issued a $22.00 price objective (down from $30.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, April 21st. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Friday, May 8th. Finally, Bank of America reissued an “underperform” rating and issued a $20.00 target price (down from $25.00) on shares of Amphastar Pharmaceuticals in a report on Monday, June 29th. Six analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average price target of $22.00.

Amphastar Pharmaceuticals Stock Performance

AMPH traded up $1.48 during trading on Friday, hitting $21.29. The company’s stock had a trading volume of 494,338 shares, compared to its average volume of 527,064. The business’s 50 day simple moving average is $19.63 and its 200-day simple moving average is $21.40. The firm has a market cap of $938.68 million, a PE ratio of 12.81, a P/E/G ratio of 4.27 and a beta of 0.89. Amphastar Pharmaceuticals has a one year low of $16.65 and a one year high of $31.26. The company has a quick ratio of 2.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.79.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.29. The firm had revenue of $183.90 million during the quarter, compared to the consensus estimate of $179.92 million. Amphastar Pharmaceuticals had a net margin of 11.00% and a return on equity of 15.12%. As a group, sell-side analysts predict that Amphastar Pharmaceuticals will post 2.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP raised its stake in Amphastar Pharmaceuticals by 12.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,027,947 shares of the company’s stock valued at $39,726,000 after purchasing an additional 228,262 shares during the period. TD Asset Management Inc lifted its holdings in Amphastar Pharmaceuticals by 1.6% in the 4th quarter. TD Asset Management Inc now owns 1,963,052 shares of the company’s stock worth $52,571,000 after purchasing an additional 31,160 shares in the last quarter. State Street Corp boosted its stake in Amphastar Pharmaceuticals by 2.1% in the 4th quarter. State Street Corp now owns 1,531,786 shares of the company’s stock worth $41,021,000 after purchasing an additional 31,044 shares during the period. Fuller & Thaler Asset Management Inc. boosted its stake in Amphastar Pharmaceuticals by 3.0% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 1,394,463 shares of the company’s stock worth $37,344,000 after purchasing an additional 40,536 shares during the period. Finally, Marshall Wace LLP grew its holdings in Amphastar Pharmaceuticals by 41.6% during the 4th quarter. Marshall Wace LLP now owns 1,237,284 shares of the company’s stock valued at $33,134,000 after buying an additional 363,216 shares in the last quarter. Institutional investors own 65.09% of the company’s stock.

Key Amphastar Pharmaceuticals News

Here are the key news stories impacting Amphastar Pharmaceuticals this week:

• Positive Sentiment: Adjusted earnings and revenue beat estimates: Amphastar reported adjusted EPS of $0.91, well above the $0.62–$0.66 analyst consensus range and up from $0.85 a year earlier. Revenue reached $183.9 million, exceeding the approximately $179.9 million consensus estimate. Amphastar Pharmaceuticals Reports Financial Results
• Positive Sentiment: Solid profitability: GAAP net income was $30.3 million, or $0.67 per share, while adjusted non-GAAP net income totaled $40.8 million, or $0.91 per share. The earnings beat strengthens the investment case by demonstrating better-than-expected operating performance in the quarter. Amphastar Q2 Earnings and Revenues Top Estimates
• Neutral Sentiment: Investor focus shifts to the outlook: The Q2 earnings call and related analysis provide additional commentary on key business metrics and management’s expectations, but the available reports do not identify a major new guidance change. Amphastar Q2 2026 Earnings Call Transcript
• Negative Sentiment: Wells Fargo remains cautious: The firm raised its price target from $19 to $20 but maintained an “equal weight” rating. The new target remains below the stock’s recent trading level, signaling that Wells Fargo views the shares as fairly valued to modestly overvalued despite the earnings beat. Benzinga analyst report

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.